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Abstract
The neurodegenerative disease Friedreich’s ataxia (FRDA) is the most common autosomal-recessively inherited ataxia and is
caused by a GAA triplet repeat expansion in the first intron of the frataxin gene. In this disease, transcription of frataxin, a
mitochondrial protein involved in iron homeostasis, is impaired, resulting in a significant reduction in mRNA and protein
levels. Global gene expression analysis was performed in peripheral blood samples from FRDA patients as compared to
controls, which suggested altered expression patterns pertaining to genotoxic stress. We then confirmed the presence of
genotoxic DNA damage by using a gene-specific quantitative PCR assay and discovered an increase in both mitochondrial
and nuclear DNA damage in the blood of these patients (p,0.0001, respectively). Additionally, frataxin mRNA levels
correlated with age of onset of disease and displayed unique sets of gene alterations involved in immune response,
oxidative phosphorylation, and protein synthesis. Many of the key pathways observed by transcription profiling were
downregulated, and we believe these data suggest that patients with prolonged frataxin deficiency undergo a systemic
survival response to chronic genotoxic stress and consequent DNA damage detectable in blood. In conclusion, our results
yield insight into the nature and progression of FRDA, as well as possible therapeutic approaches. Furthermore, the
identification of potential biomarkers, including the DNA damage found in peripheral blood, may have predictive value in
future clinical trials.
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Introduction
Friedreich’s ataxia (FRDA; OMIM# 229300) is the most
common autosomal-recessively inherited ataxia beginning in
childhood and leading to death in early adulthood. Patients
exhibit neurodegeneration of the large sensory neurons and
spinocerebellar tracts, along with variable systemic manifestations
that include hypertrophic cardiomyopathy, scoliosis, and diabetes
mellitus (see http://www.ncbi.nlm.nih.gov/entrez/dispomim.
cgi?id=229300).
FRDA results from the partial loss of frataxin (FXN; Entrez
Gene ID 2395), a small nuclear encoded 18-kDa protein targeted
to the mitochondrial matrix [1]. A GAA triplet repeat expansion
in the first intron impairs transcription of frataxin, resulting in a
significant reduction in mRNA and protein levels [2–4]. The exact
physiological function of frataxin is still unclear, but it has been
shown to bind iron and play a role in iron-sulfur cluster (ISC)
assembly [5,6]. A decrease in frataxin may also increase reactive
oxygen species (ROS) produced by increases in bioavailable iron
[5,7–10] and the lack of iron detoxification [11]. The conclusions
of several studies indicate that a defect in ISC assembly is the
primary event in frataxin-deficient cells [5,12–14] and that ROS
production is a secondary event [8,15]. Napoli et al. [12] believe
the dysfunction of biosynthesis of mitochondrial iron-sulfur
clusters, and deficiency of ISC enzyme activity, produces a defect
in heme, which in turn causes a loss of cytochrome C. Impairment
of electron transport activity results in higher levels of ROS
production [14], and according to Napoli et al. [12], it is the
decrease in cytochrome C that leads to the unchecked increase in
production of mitochondrial ROS in Friedreich’s ataxia patients.
This hypothesis is further supported by studies of yeast strains with
reduced frataxin, which accumulate mitochondrial iron and
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proteins, and mitochondrial DNA (mtDNA), ultimately resulting
in the decreased capacity for ATP synthesis through impaired
oxidative phosphorylation [15,16]. Moreover, evidence consistent
with nuclear DNA (nDNA) damage is demonstrated by decreasing
the levels of frataxin in a RAD52 (854976) double-strand break
repair deficient yeast strain, which results in rapid G2/M cell cycle
arrest [16].
In FRDA patients, iron deposition is observed in neuronal and
myocardial cells and suggests the potential for free radical damage
[17,18]; however, we note that the case for oxidative stress has
been somewhat controversial. Cell models support sensitivity to
oxidative stress, and patient studies have found markers of
oxidative stress [7,19,20], but a conditional knock-out (KO)
mouse model did not show oxidative stress, or improvement, when
overexpressing superoxide dismutase (SOD) [21]. Recent studies
have also failed to replicate the previous marker data [22,23].
Therefore, it is important to examine other markers of oxidative
stress by more sensitive and specific means, such as testing for
mtDNA damage in the patient. There is good evidence to suggest
that hypertrophic cardiomyopathy, which leads to the death of
most FRDA patients, is probably a consequence of iron-catalyzed
Fenton chemistry causing damage to mitochondrial macromole-
cules followed by muscle fiber necrosis and a chronic reactive
myocarditis [24]. More work is needed to understand the causes of
the pathobiology associated with the progression of FRDA.
While genome-wide scans in frataxin-deficient model organisms
and mammalian cells have previously been published [15,25–27],
we report the first study involving transcription profiling of total
blood from children with FRDA. These gene expression data were
further validated in a second cohort of adults with FRDA, who
were compared to an independent group of controls. Importantly,
we observed previously unreported signatures of gene expression
associated with DNA damage responses. Based on these results, we
further analyzed patient mitochondrial and nuclear DNA from
peripheral blood and detected high levels of damage as compared
to control samples. These results provide insights into the nature of
the disease and a working model for frataxin deficiency in humans.
Results
Microarray analysis of global gene expression in total
blood from children with FRDA
We set out to identify mechanisms involved in the nature and
progression of Friedreich’s ataxia by analyzing global gene
expression changes in blood samples from 28 FRDA children
involved in an idebenone clinical trial [22] (Table S1). Blood
samples were collected from the children prior to the administra-
tion of idebenone. The protocol only allowed one 8.5 ml sample of
blood for the RNA isolation, which resulted in a limited amount of
RNA for this study. Furthermore, control unaffected children were
not included in this clinical trial; therefore, we used the youngest
control adults available from an NIEHS sponsored study [28] for
the gene expression analysis (Table S1).
Significance Analysis of Microarray (SAM) [29] identified 1,370
differentially expressed genes at a false discovery rate (FDR) less
than 0.023% (Dataset S1). A majority of genes, 899, were
downregulated in FRDA compared with control, while 471 genes
were upregulated. We further investigated whether these altered
transcripts (FDR,0.023%) were associated to specific gene
ontology (GO) terms, at p#0.05, in order to assess the global
impact of FRDA on gene expression. This analysis identified
significant functional groups that included apoptosis signaling,
transcription/RNA processing, cell-cell signaling, cell cycle,
ubiquitin cycle, proteolysis/protein catabolism, response to
stimuli, and fatty acid beta-oxidation (Figure 1).
Although age-matched control children were not available for
this study, we decided not to use data uploaded to GEO by other
laboratories. It is important to minimize cross-platform differenc-
es, which can give rise to large technical variation that may
obscure small biological differences in blood cells. Therefore, the
controls we used were gene expression profiles from young adults
processed in our same facility, on the same oligonucleotide chip
design, by the same operator. However, we did assess what effect
age might have on gene expression by using SAM to test for any
association. This analysis was performed in the controls, and age
was dichotomized by comparison to the median age of the
controls. Age was not found to be associated with any gene
expression value after multiple testing correction (min q=0.47);
thus no age-specific gene expression changes were discerned in our
control group.
Gene Set Analysis reveals common gene signatures to
genotoxic stress responses in children and a validation
cohort of adults with FRDA
As an alternative approach to gene ontology enrichment
analysis, the microarray data for children with FRDA were
further analyzed by employing Gene Set Analysis (GSA), a tool
that uses predefined gene sets to identify significant biological
changes in microarray datasets [30,31]. We searched for
significantly associated gene sets from Molecular Signatures
Database subcatalog C2, a database of 1684 microarray
experiment gene sets, pathways, and other groups of genes [31].
The analysis yielded many biologically informative sets (Dataset
S2) consisting of genes enriched in brain cortex and heart atria, as
well as biological processes such as mitochondrial fatty acid beta-
oxidation, and reactive oxygen species. The application of GSA
also identified 23 gene sets associated to genotoxic stress response
(Table 1). P53genes_all is composed of transcriptional targets of p53
(7157), a regulator of gene expression in response to various signals
Author Summary
Friedreich’s ataxia is an inherited disease that causes
progressive damage to the nervous system and affects the
muscles and heart. The disease is caused by a defect in the
frataxin gene, which is involved in iron homeostasis and
likely protects against reactive oxygen species. In order to
identify mechanisms involved in the nature and progres-
sion of the disease, we performed transcriptional profiling
and measurements of mitochondrial and nuclear DNA
damage on blood cells from FRDA patients. Transcriptional
profiling was performed on blood samples from a cohort
of 28 children compared to a control group. These data
were then validated with a cohort of 14 adults with FRDA
compared to a second independent control group. DNA
damage was assessed on the blood samples from the 28
FRDA children, plus an additional 19 affected children, by
quantitative PCR (QPCR). Transcriptional profiling revealed
changes in gene expression consistent with the presence
of genotoxic stress in FRDA patients. This finding was
supported by the direct evidence that FRDA patients
accumulated significantly higher levels of mitochondrial
and nuclear DNA damage as compared to controls. The
identification of potential biomarkers, including the DNA
damage found in peripheral blood, may help identify
therapeutic approaches for this devastating disease.
DNA Damage in Blood from FRDA Patients
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(5366), and SESN1 (27244) displaying repressed expression.
Genotoxins_all_24h_reg consists of downregulated genes regulated
in mouse lymphocytes at 24 hours by cisplatin, methyl methane-
sulfonate (MMS), mitomycin C, taxol, hydroxyurea, and etoposide
[32]. Other gene sets consist of mostly downregulated genes in
response to bleomycin, MMS, ultraviolet B (UVB), and ultraviolet
C (UVC) radiation, which were also downregulated in the FRDA
dataset (denoted by the negative GSA scores) (Table 1). We next
asked if there were genes in common across the 23 genotoxic-
stress-response gene sets. Transcripts present in at least 25% of the
gene lists (81 genes total) were subjected to unsupervised clustering
and displayed segregation into two groups of controls and patients
(Figure 2A, right panels, and Dataset S3). Most of these genes fall
in the gene ontology categories of transcription, signal transduc-
tion, and cell cycle (data not shown).
To validate the gene expression changes observed in the child
FRDA cohort, we examined an adult FRDA cohort (n=14).
These patients were compared with a new group of 15 adult
controls, obtained from an NIEHS sponsored study [28] (Table
S2). SAM analysis yielded 2,874 genes at an FDR of less than
0.018% (Dataset S4). This dataset was also analyzed with GSA,
yielding significant gene sets related to genotoxic stress response,
DNA repair, insulin response, and apoptosis (Dataset S5). When
we performed unsupervised clustering of the same list of 81 genes
found in the children with FRDA, we observed a similar
segregation of patients from controls in this independent group
of adults (Figure 2A), thus helping to validate this gene set.
The FRDA adult and FRDA children’s datasets were further
compared by limiting to significant SAM genes in common and
taking into account the direction of differential expression. As stated
earlier, a total of 1370 probesets were found significant in the
children’s cohort (FDR,0.023%), and the median FDR for these
probesets in the second cohort was 0.34%. These analyses resulted
in 228 mostly downregulated genes in common in both gene sets
(FDR,0.018%; overlap p=0.007 – based on the probability of the
hypergeometric distribution) (Figure 2B). This list of 228 genes was
analyzed for specific GO category enrichment (Figure 2C) (catego-
ries similar to those displayed in Figure 1 are not included; for the
full list, see Table S3) and significantly associated to ubiquitin cycle,
protein ubiquitination, and proteolysis/catabolism, as well as cell
cycle. Using the Ingenuity Knowledge Base (see Materials and
Methods), we further mapped the genes to biological function
categoriesand specificpathways,whichincluded apoptosissignaling
and oxidative phosphorylation (Table S4). Additionally, the Fisher’s
exact test was used to search the Molecular Signatures Database for
gene sets enriched with genes found in the overlap. These results
yielded similar genotoxic gene sets as those observed with the
children’s data as a whole (Table S5).
FRDA patients have significant mitochondrial and
nuclear DNA lesions
Having seen a genotoxic stress response in the microarray data
of the FRDA patients, we sought to validate these findings and test
Figure 1. Selected gene classifications according to biological
processes. Significantly regulated genes (SAM FDR,0.023%; n=1,370)
fromFRDAchildrenversushealthyyoungadultsweregroupedaccording
to the gene ontology category of biological process (p#0.05 in updown,
over,o runder [expression] output lists). The percent of total (displayed
with a gray ball) is based on the number of significantly changed genes
out of the total number of genes assigned to each gene ontology term.
The change in expression for each GO term is depicted in yellow for
upregulation and blue for downregulation.
doi:10.1371/journal.pgen.1000812.g001
Table 1. Gene Set Analysis demonstrates a signature of DNA
damage in FRDA patients.
Set Name Score p-Value FDR
BLEO_HUMAN_LYMPH_HIGH_4HRS_UP 20.37 0.044 0.6916
GENOTOXINS_ALL_24HRS_REG 20.4663 0.044 0.6916
MMS_HUMAN_LYMPH_LOW_4HRS_DN 21.1264 0.01 0.5726
MMS_MOUSE_LYMPH_HIGH_4HRS_UP 20.7369 0.002 0.4453
P53GENES_ALL 0.3779 0.04 0.9698
UVB_NHEK1_C6 20.4047 0.022 0.6203
UVB_NHEK1_DN 20.4473 0.014 0.5726
UVB_NHEK2_DN 20.3615 0.012 0.5726
UVB_NHEK3_C2 20.7741 0.004 0.5726
UVC_HIGH_ALL_DN 20.4171 0.006 0.5726
UVC_HIGH_D1_DN 20.4286 0.032 0.668
UVC_HIGH_D2_DN 20.366 0.064 0.7433
UVC_HIGH_D7_DN 20.4576 0.018 0.5726
UVC_HIGH_D9_DN 20.733 0.008 0.5726
UVC_TTD_4HR_DN 20.5704 0.006 0.5726
UVC_TTD_8HR_DN 20.3107 0.044 0.6916
UVC_TTD_ALL_DN 20.4737 0.008 0.5726
UVC_TTD-XPCS_COMMON_DN 20.4533 0.012 0.5726
UVC_XPCS_4HR_DN 20.5225 0.014 0.5726
UVC_XPCS_4HR_UP 20.6511 0.028 0.645
UVC_XPCS_8HR_DN 20.5428 0.008 0.5726
UVC_XPCS_ALL_DN 20.5414 0.006 0.5726
UV-CMV_UNIQUE_HCMV_6HRS_DN 20.2488 0.02 0.5938
GSA was performed using the Molecular Signatures Database. Significantly
enriched gene sets included 23 sets associated to genotoxic stress response.
doi:10.1371/journal.pgen.1000812.t001
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PLoS Genetics | www.plosgenetics.org 3 January 2010 | Volume 6 | Issue 1 | e1000812Figure 2. Analogous gene expression responses in blood from children and adults with FRDA. (A) A common gene signature is
representative of a genotoxic stress response found by Gene Set Analysis. Twenty-three genotoxic stress response gene sets were searched for
common genes. This heat map, generated by unsupervised clustering, displays the genes present in at least 6 of the 23 gene sets and compares
transcript levels between FRDA patients, the adult and children cohorts, and controls. Yellow=upregulated; Blue=downregulated. C=Control;
P=Patient. Note that while three patients and one control did not segregate with their respective groups, all adult patients and controls clustered in
two separate groups in this unsupervised clustering. (B) Heat-map generated by unsupervised clustering of FRDA and control samples, which displays
the overlap of significantly differentially expressed genes (SAM FDR,0.023%; n=228) in the FRDA children and FRDA adults (overlap p#0.007).
C=control; P=patient. (C) A selected list of significant GO groups representing the overlap gene list described in (B). All controls used for comparison
to the FRDA children are young adults (see Table S1). The percent of total (displayed with a gray ball) is based on the number of significantly changed
genes out of the total number of genes assigned to each gene ontology term. The gene number for each GO group is shown with a blue bar, the
intensity of which is indicative of the p-value.
doi:10.1371/journal.pgen.1000812.g002
DNA Damage in Blood from FRDA Patients
PLoS Genetics | www.plosgenetics.org 4 January 2010 | Volume 6 | Issue 1 | e1000812whether damage to the nuclear and mitochondrial genomes is
elevated in patients with FRDA. Moreover, although genotoxic
responsive gene sets in the children and adult cohorts had highly
significant p-values, some had high false discovery rates, requiring
further biological validation.
Blood DNA from the same 28 children studied for gene
expression was analyzed using a quantitative PCR (QPCR) assay
to detect DNA damage [33]. In addition to the 28 children
evaluated by gene expression profiling, we obtained 19 more DNA
samples from affected children in the same clinical study (Table
S6) [22]. Only one 8.5 ml sample, per child, of whole blood was
allotted for DNA isolation; all DNA samples were prepared by one
person using the same protocol (see Materials and Methods).
Blood from 15 young adults was obtained from an NIH blood
bank in Bethesda, MD and used as controls (Table S6).
The QPCR technique we used has successfully identified lesions
in nDNA and mtDNA, resulting from oxidative stress, in a
number of organisms, including human and rat cell cultures
[34–36], yeast [16], and mice [37]. However, this is the first time
the assay has been used for DNA derived from human blood. The
approach involves the amplification of a large 8.9 kb and 12.2 kb
fragment for mtDNA and nDNA, respectively. Previous work by
our group suggests that damage is distributed evenly throughout
both genomes [34,38,39]. The large mtDNA amplification
product constitutes ,54% of the genome and is the representative
of the overall genome. The primers used to amplify the product
were designed to specifically avoid the D-loop region – a region
that is often single-stranded and could increase DNA damage
because of its high mutation frequency. Additionally, amplification
of a short, ,200 bp mtDNA fragment, which due to its small size
has less chance of containing a lesion, is used to normalize for
mitochondrial copy number in the amplification of the large
mtDNA fragment. Oxidative damage induces a spectrum of
lesions, such as strand breaks, abasic sites, and some base damage
(i.e. thymine glycol), which interfere with the progression of the
thermostable polymerase to replicate the template DNA. Thus,
during amplification, the presence of an oxidative lesion results in
the inability of the polymerase to synthesize the template DNA.
The final amount of amplified DNA is inversely proportional to
the number of oxidative lesions. The QPCR gene-specific damage
assay is based on differential amplification of target genes in
affected controls as compared to a control population. Excess
DNA damage in the affected group will show as a decrease in
amplification as compared to the control group.
A significant number of nuclear (0.53 lesions/10 kb) and
mitochondrial DNA lesions (0.81 lesions/10 kb) was observed in
the 47 FRDA children compared to 15 young adult controls
(Table S6), with p,0.0001, respectively, by Mann Whitney U-test
(Figure 3). There was also a significantly higher number of
mitochondrial lesions than nuclear lesions (p,0.002, Mann
Whitney U), and both mtDNA and nDNA lesions were found to
be highly correlated by Spearman’s rank test (Rho=0.700;
p,0.0001). Since this study did not have age-matched control
children, for the two DNA damage variables (nDNA and mtDNA),
we used a t-test to detect any association with age in the control
group. This analysis was performed in the controls after stratifying
the subjects as ‘‘higher’’ or ‘‘lower’’ than the median age of the
group. Age was not found to be associated with mtDNA damage
(p=0.98) or nDNA damage (p=0.10).
Finally, mtDNA and nDNA damage samples were classified as
‘‘high damage’’ or ‘‘low damage’’ if the lesions/10 kb of DNA was
.0.85 or ,0.85 (based on the distribution pattern; data not shown),
respectively. GSA was then used to test the association of the DNA
damage to predefined gene sets. A positive score would indicate
enrichment in samples with high DNA lesions/10 kb, and a negative
score would point to enrichment in samples with less lesions/10 kb.
This analysis showed higher levels of DNA lesions associating to gene
sets involving neuronal and synapse formation, as well as several
others regarding a genotoxic stress response (p#0.01) (Dataset S6).
Extracting gene expression patterns identifies potential
biomarkers of disease progression
Since the bioinformatics analyses in this study were applied to
SAM-derived data based on pooling the raw data from all 28
children (Materials and Methods), we tested the hypothesis that a
discrete set of genes would be differentially expressed in patients
with the lowest levels of frataxin. We next generated a
transcription profile comparing patients with the lowest amount
of frataxin, analyzed by Real-time PCR, to those with the highest.
The samples were stratified into two groups, based on the
expression distribution, where the values formed two distinct
modes (see Figure S1 legend). A threshold of 22.5 was selected to
separate these two modes, resulting in six patients considered
‘‘high-frataxin expressers’’ and 21 patients designated ‘‘low-
frataxin expressers’’ (Figure 4A and Figure S1). Significant gene
changes were determined using SAM at a cutoff of FDR#8%
(p#0.05) for a total of 973 genes. These genes were analyzed for
gene ontology enrichment and mapped to pathways in the
Ingenuity Knowledge Base. Top scoring categories and pathways
included protein biosynthesis, oxidative phosphorylation, ubiqui-
none biosynthesis, nucleotide excision repair, and protein
ubiquitination, all of which were downregulated in those patients
expressing lower levels of frataxin (Figure 4B).
Since we had quantified the level of frataxin for each patient, we
sought to find an association of these levels to the expression of
each gene in our genotoxic signaling list (Dataset S3). A univariate
linear model was constructed to test this association, and no genes
in this set were found to be significantly associated with frataxin
levels. The minimum p-value was 0.002, which was not significant
Figure 3. Nuclear and mitochondrial DNA damage are identi-
fied by QPCR analysis of blood DNA from 47 patients with
FRDA and 15 controls. These data represent the number of excess
lesions found per 10 kb of DNA from both mtDNA and nDNA genomes
in FRDA patients as compared to the controls. A significant number of
nuclear (0.53 lesions/10 kb) and mitochondrial DNA lesions (0.81
lesions/10 kb) were observed (p,0.0001, respectively, by Mann-
Whitney U test). There is a significantly higher number of mitochondrial
lesions than nuclear lesions (p,0.002 by Mann-Whitney U test), and
both types of lesions are highly correlated (p,0.0001 by Spearman’s
Rank Correlation). Error bars represent the standard error of the mean.
doi:10.1371/journal.pgen.1000812.g003
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find correlations of frataxin mRNA levels to all available clinical
data for each child, including DNA lesions and disease duration,
but only found an association, by univariate linear modeling, with
age of onset and number of short GAA repeats. This resulted in
p=0.00277 and r
2=0.305 for the relationship of frataxin mRNA
levels to age of onset (Figure 4C), and p=0.00131 (r
2=0.344) for
the relationship of frataxin mRNA levels with the short GAA
repeat length (Figure S2). These correlations of frataxin mRNA to
short GAA repeat length and age of onset are in agreement with
other published studies [1,40,41].
Intrigued by these associations to clinical data, we wondered if
we could directly associate the global gene expression data to all
clinical data and decided to use a method called EPIG, which
extracts microarray gene expression patterns and identifies co-
expressed genes (see Materials and Methods) [42]. Indeed, not
only did we validate the SAM gene lists for the FRDA children,
but we extracted patterns that associated the mostly downregu-
lated transcriptional changes to their frataxin levels, age of
diagnosis, and International Cooperative Ataxia Rating Scale
scores – a scoring method used to discern the level of disability in
the FRDA patient (Table 2) [43]. Patterns correlating levels of
frataxin to gene expression encompassed 37 responsive genes.
These genes were grouped most strongly in the GO categories of
immune response and protein biosynthesis. Patient age of
diagnosis and ICARS score associated with 98 and 48 genes,
Figure 4. Patients with lower levels of frataxin correlate with age of onset of disease and have more compromised mitochondrial
and protein biosynthetic function. (A) Real-time PCR of frataxin levels in all patients with available RNA (27) were compared to controls (10).
Levels of frataxin are relative to the average DCT of the controls (dotted line). The error bars represent standard deviations. Brackets encompass the
patients stratified by their expression distribution into those expressing higher levels of frataxin (n=6) and those expressing lower levels of frataxin
(n=21) (see Figure S1). (B) Global gene expression changes were analyzed in the patients with low levels of frataxin vs. patients with high levels of
frataxin. Significantly differentially expressed genes (SAM FDR#8%; p#0.05; n=973) were further examined for gene ontology groups categorized by
biological process. The same list of genes was analyzed with IPA (Ingenuity Systems), which identified significant biological functions and canonical
pathways. All gene groups contain mostly downregulated genes, indicating compromised mitochondrial and biosynthetic function in patients with
the lowest expression of frataxin. (C) Age of onset plotted against the Real-time PCR frataxin levels yields a correlation of r
2=0.305 (p=0.00277).
doi:10.1371/journal.pgen.1000812.g004
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category. Supervised correlation analysis was also performed,
where correlation r values and p-values between each gene
expression profile and ICARS score were calculated. This analysis
generated a list of 144 positively and negatively correlated genes at
a p-value threshold of 0.01. Protein biosynthetic function was once
again highly significant as a GO category, resulting from the input
of these genes (Table 2). Genes correlated with ICARS are
potential biomarker candidates that may help to classify the
progression of the disease.
Analysis of the second patient cohort shows consistent
alterations in gene expression with FRDA children
EPIG was further utilized to extract patterns and compare
between the FRDA children and FRDA adults. We were
interested in finding biomarker gene candidates based on duration
of disease and representative of severity. Of particular interest
were genes that were very significant in both cohorts, regulated in
the same direction, but displaying larger differential expression in
the adults. A detailed examination of the gene profiles was
employed using the signal to noise ratio, ANOVA, Student’s t-test,
and fold changes, and resulted in fifteen genes that are potential
biomarkers of disease progression in need of further testing:
SERPINC1 (462), DHFRL1 (200895), IRX2 (153572), SGCE (8910),
ADAM23 (8745), TBX3 (6926), SLC5A4 (6527), CCAR1 (55749),
MS4A2 (2206), IMPACT (55364), NDUFA5 (4698), CEACAM6
(4680), C10orf88 (80007), ITGA4 (3676), and CD69 (969) (first
seven genes are upregulated and the subsequent eight genes are
downregulated). Entrez IDs for these genes and all genes described
in this paper can be found in Table S7.
Discussion
This study provides the first summary of gene expression
changes in the blood of 28 children with Friedreich’s ataxia and
the association of this global response to the nuclear and
mitochondrial DNA damage found in 47 children (including the
28 children from the gene expression analysis). These data – the 23
gene sets associated to a genotoxic stress response and the direct
biological evidence of mtDNA and nDNA damage in the blood –
result in a working model of the disease, where repressed levels of
frataxin create a vicious cycle of mitochondrial dysfunction
(probably due to ISC biosynthesis impairment), decreased
oxidative phosphorylation, and increased reactive oxygen species
production and genotoxic stress (Figure 5). These events result in
DNA damage and altered DNA transactions, which likely
contribute to the decreased protein biosynthesis, signaling,
transcription, DNA replication/recombination/repair, apoptosis,
and ubiquitination, as well as the altered immune response and
proliferation indicated in the transcription profiling. Such changes
Table 2. Potential biomarkers of FRDA: gene associations to clinical data based on differential expression.
Clinical Data Gene Category p-Value Gene Symbol
Frataxin Levels n=37
Immune Response (BP) 9.79E-06 CXCL11; FPR1; HLA-C; IFITM1; LILRB3; POU2F2; S100A12; S100A9; S100B; TLR4
Protein Biosynthesis (BP) 6.14E-04 RPS20; RPS23; RPS26; RPS27A; RPS4X; S100B; TLR4
Inflammatory Response (BP) 7.55E-04 CXCL11; FPR1; S100A12; S100A9; TLR4
Eukaryotic 48s Initiation Complex (CC) 3.83E-05 RPS20; RPS23; RPS26; RPS4X
Ribosome (CC) 2.35E-03 RPS20; RPS23; RPS26; RPS27A; RPS4X
Age of Diagnosis n=98
Protein Biosynthesis (BP) 1.83E-02 MAN1B1; RPL37; RPL3L; RPS20; RPS23; RPS4X; RPS5
Cytosolic Ribosome (CC) 2.64E-04 RPL37; RPS20; RPS23; RPS4X; RPS5
ICARS
1 n=49
Protein Biosynthesis (BP) 2.74E-05 MRPS14; RPL24; RPL26L1; RPL27; RPL37; RPS19; RPS23; RPS27A; RPS3
Ribosome (CC) 3.04E-10 HAT1; MRPS14; MRPS28; RPL24; RPL26L1; RPL27; RPL37; RPS19; RPS23; RPS27A; RPS3
ICARS
2 n=144
Protein Biosynthesis (BP) 1.41E-11 FAU; GSPT2; NHP2L1; RPL13A; RPL18A; RPL19; RPL22; RPL23A; RPL28; RPL29; RPL36;
RPL37; RPL37A; RPLP2; RPS10; RPS12; RPS13; RPS14; RPS15; RPS19; RPS23; RPS28; RPS3
Ribosome (CC) 3.78E-19 FAU; MTHFR; NHP2L1; ONECUT1; RPL13A; RPL18A; RPL19; RPL22; RPL23A; RPL28;
RPL29; RPL36; RPL37; RPL37A; RPLP2; RPS10; RPS12; RPS13; RPS14; RPS15; RPS19;
RPS23; RPS28; RPS3
Cytoplasm (CC) 8.50E-08 ACTN4; ADSS; AP2B1; APRT; ATP5G2; CCND3; CDC42BPB; CES1; CFL1; CRIP2; CTSF;
DSG1; FAU; FHL2; GLI2; HIPK2; HSPC152; ITGAE; KIAA0907; LOC51334; MAP4; MTHFR;
NGFRAP1; NHP2L1; NME3; NXT1; ONECUT1; PAPSS2; PEX6; RPL13A; RPL18A; RPL19;
RPL22; RPL23A; RPL28; RPL29; RPL36; RPL37; RPL37A; RPLP2; RPS10; RPS12; RPS13;
RPS14; RPS15; RPS19; RPS23; RPS28; RPS3; SLC27A5; STX6; TMEM9; UXT; XPO7
Structural Constituent of Ribosome (MF) 2.06E-19 FAU; MRPS24; NHP2L1; RPL13A; RPL18A; RPL19; RPL22; RPL23A; RPL28; RPL29; RPL36;
RPL37; RPL37A; RPLP2; RPS10; RPS12; RPS13; RPS14; RPS15; RPS19; RPS23; RPS28; RPS3
n=significant genes; selected categories and their genes are displayed.
Frataxin levels, Age of Diagnosis, ICARS
1; n=genes found by EPIG analysis.
ICARS
2; n=genes found by supervised correlation analysis, where the r and P values between gene expression and ICARS score were calculated.
BP=Gene ontology system, biological process.
CC=Gene ontology system, cellular component.
MF=Gene ontology system, molecular function.
doi:10.1371/journal.pgen.1000812.t002
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neurodegenerative and cardiovascular disease in FRDA patients,
while also providing biomarker candidates for their disease.
Gene expression changes in peripheral blood of FRDA
patients compared to lymphoblastoid cell lines
Cortopassi and coworkers have previously published two global
gene expression analyses of cells from FRDA patients [25] and
tissue from frataxin-KO mice (26). While direct analyses of these
published studies with the work presented here is not possible,
since these previous data were not apparently deposited in a public
database, several points are worth noting. Tan et al. [25] reported
48 significant frataxin-dependent differentially expressed genes in
at least two of the human cell types. In particular, they focused on
seven downregulated transcripts belonging to the sulfur amino
acid (SAA) and iron-sulfur cluster biosynthetic pathways. When
they combined data from mouse and human frataxin-deficient
cells and tissues, mitochondrial coproporphyrinogen oxidase
(CPOX; 1371), which is involved in the heme pathway, and the
homologue of yeast COX23 (856516) were most consistently
downregulated [27]. These transcripts were not found to be
significant in our dataset. The authors conclude that frataxin
deficiency leads to heme deficiency. While our work with both
FRDA patient cohorts did not show the heme pathway as
significantly repressed, the downregulated mitochondrial pathways
we did observe are easily affected by, or could contribute to, heme
deficiency. Ultimately, these changes in heme biosynthesis could
cause DNA damage [44] recapitulated in our patients.
We wanted to further validate the datasets derived from
children and adults with FRDA, so we analyzed ten FRDA
lymphoblastoid cell lines, compared with seven age-matched
controls, and data from a previous report involving two
lymphoblastoid cell lines (one control and one affected) (Table
S8) [45]. Particularly interesting overlaps with the blood data were
observed with GSA analysis, which also yielded significant gene
sets related to genotoxic stress response (for biologically informa-
tive sets in common between the FRDA children’s data and the
lymphoblastoid data, see Dataset S7 and Figure S3). Furthermore,
GSA analysis of the lymphoblastoid data also found an association
to significant gene sets like electron_transport_chain, mitochondrion, and
ubiquinone biosynthesis, which are indicative of the mitochondrial
dysfunction expected in frataxin-deficient cells (Dataset S7).
Consequences of mitochondrial and nuclear DNA
damage in FRDA patients
While the QPCR assay used in this study cannot directly
identify the type of DNA damage inhibiting the progression of the
thermostable polymerase, the increase in mtDNA damage, as
compared to nDNA damage, is consistent with a large number of
studies from our and other laboratories, indicating that mtDNA is
more prone to oxidative stress [16,34–37]. The increased DNA
damage observed in the children suggests oxidant injury in their
blood cells, probably caused by an increase in bioavailable iron in
the mitochondria. Persistent mtDNA damage in FRDA patients
could impair mitochondrial function. Experiments with mamma-
lian cell cultures, treated with hydrogen peroxide, indicate that
relentless mtDNA damage decreases oxidative phosphorylation
and ATP production (unpublished observation). In vivo evidence of
impaired mitochondrial ATP production has, in fact, been seen in
the muscle of FRDA patients [46,47] and in KO mice [48].
Karthikeyan et al. [16] also demonstrate how yeast strains with
reduced frataxin accumulate mitochondrial iron and generate
reactive hydroxyl radicals, which damage cell membranes,
proteins, and mitochondrial DNA, resulting in the decreased
capacity for ATP synthesis through impaired oxidative phosphor-
ylation. The same study further demonstrates how low levels of
frataxin in a RAD52 double-strand break repair deficient yeast
strain lead to rapid G2/M cell cycle arrest, which is consistent with
Figure 5. Model of Friedreich’s ataxia pathology based on this study. Data presented in this study are consistent with a dysregulation of
mitochondrial function, decreased oxidative phosphorylation, increased ROS production, and subsequent mitochondrial and nuclear DNA damage.
These factors contribute to decreased signaling and altered DNA transactions, which are likely to result in subsequent loss of protein synthesis and
decreased protein degradation, as suggested in the transcription profiling. These alterations may cause tissue damage, altered immune response,
and the clinical pathology associated with FRDA.
doi:10.1371/journal.pgen.1000812.g005
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sensitivity to gamma irradiation in FRDA skin fibroblasts, and
the induction of chromosomal damage by mutagens in blood
lymphocytes, support a hypothesis of increased susceptibility and/
or altered DNA repair capacity in these patients [49,50].
The eukaryotic cell, in response to DNA damage, employs
different strategies for damage recognition and repair in order to
maintain the integrity of the genome. DNA damage sensors such as
ATM (472) and p53 are crucial in detecting double-strand breaks
and general DNA damage responses, respectively [51]. Although
the ATM and p53 genes are not differentially expressed in the
datasets presented here, we observed, via GSA and the Ingenuity
Knowledge Base (data not shown), that many interacting network
partners of these two proteins are significantly altered.
The significant increase in persistent DNA damage we found in
FRDA patients, as well as the transcription profiling results,
indicate altered repair capacity and altered apoptosis signaling
events. Furthermore, a significant number of genes included in the
Ingenuity biological function category of Cancer (104 and 475
genes in Cancer and its subcategories, p#0.05, for FRDA children
and FRDA adults, respectively; data not shown) may explain the
malignant transformation potential of frataxin-deficient cells, both
in vitro and in vivo [10,48,52]. This hypothesis is supported by work
done in mice by Thierbach et al. [48], albeit a mouse model
completely deleted for frataxin. When they disrupted expression of
frataxin in mouse hepatocytes, lifespan was not only reduced, but
the livers had increased oxidative stress and mitochondrial
dysfunction. This was paralleled by reduced activity of iron-sulfur
cluster containing proteins and the development of multiple
hepatic tumors. The authors also reported impaired phosphory-
lation of the stress-inducible p38 MAP kinase and suggest that
frataxin may, in fact, be a mitochondrial tumor suppressor protein.
Thus, while reports of cancer in FRDA patients are rare [53–56],
the incidence may be underestimated due to premature mortality
of these patients in early adulthood.
The overall decrease in transcription and DNA damage we
observed are likely consequences of dysfunctional ISC biosynthesis
and reduced activity of proteins containing iron-sulfur centers. In
fact, several damage recognition and DNA repair proteins are
iron-sulfur containing and could be directly linked to the DNA
damage described [57–60]. Currently, we are analyzing protein
levels, in frataxin-deficient cell lines, of a panel of iron-sulfur
containing proteins important to DNA repair. Some candidate
proteins with iron-sulfur centers include the MutY (4595)
homologue (a glycosylase in base excision repair); the yeast
protein, Rad3 (856918), which is essential for viability, and its
human homologues XPD (2068) and Fancj (83990) (helicases
involved in nucleotide excision repair and the Fanconi anemia
repair pathway, respectively); and Pri2 (853821) (essential to RNA
primer synthesis) [57–60].
The likely sequence of events leading to the DNA damage we
observed are as follows: 1) deficiency of frataxin generates a defect in
ISC assembly and biogenesis [5,12–14]; 2) the dysfunction of
biosynthesis of mitochondrial iron-sulfur clusters, and deficient ISC
enzyme activity, produces a defectinheme and a lack of cytochrome
C [12]; 3) impairment of electron transport activity, which is
dependent on iron-sulfurbiogenesis,and the decrease incytochrome
C, results in higher levels of ROS production [12,14]; and 4) due to
lack in antioxidative capacity, which we explain below, eventual
DNA damage occurs. Therefore, we believe theDNA damage inthe
blood of the Friedreich’s ataxia patient is a secondary event to the
primary one of frataxin depletion and neurodegeneration. However,
the secondaryevent of cellularoxidativestressand DNA damage is a
significant component to the underlying pathology of the disease.
Adaptation to chronic stress
We further propose that the downregulation of many key
pathways (Figure S4A and Figure 4C) and GO categories
(Figure 1, Figure 2C, and Figure 4B), in this study, may suggest a
systemic survival response to chronic genotoxic stress and conse-
quent DNA damage. Chronic genotoxic stress in FRDA probably
results from iron accumulation in the mitochondria, and it might be
expected that cellular redox homeostasis, such as that regulated by
NRF2 (4780), would protect the cell from excessive reactive oxygen
metabolites. However, we observed the downregulation of the
NRF2-mediated oxidativestresspathway (Figure S4B), strengthening
published reports suggesting a disabled antioxidant defense response
in FRDA [9,10,61], including a recent study by Paupe et al. [62]
showing that cultured fibroblasts from patients with FRDA exhibit
hypersensitivity to oxidative stress because of an impaired NRF2
signaling pathway. Furthermore, Chantrel-Groussard et al. [9]
found that reduced frataxin does not induce superoxide dismutases
nor the import iron machinery by endogenous oxidative stress in
FRDA fibroblasts compared to controls. Superoxide dismutase
activity isalso not induced inthe heartofconditional knock-out mice
[21]. Conversely, overexpression of human frataxin in murine cells
increasesantioxidantdefenseviaactivationofglutathioneperoxidase
and elevation of reduced thiols, and reduces the incidence of ROS-
induced malignant transformation [10]. Sturm et al. [61] reported
data strongly indicating that a reduction in frataxin does not affect
the mitochondrial labile iron pool in human cell lines and suggests
that these cells have a decreased antioxidative capacity. Overall,
these studies support a mechanism by which iron-sulfur proteins are
lost [13] and there are increased amounts of ROS and a disabled
antioxidant defense system.
Based on our blood analysis of FDRA patients showing chronic
genotoxic stress responses and chronic DNA damage, we believe
these stressors cause a genetic reprogramming of fundamental
biological pathways as a protective survival response. A similar
idea was reported by Niedernhofer et al., [63] who analyzed a case
of XPF/ERCC1 (2072/2067) progeroid syndrome and a knockout
mouse model of this disease. They concluded that chronic DNA
damage causes cells to deemphasize growth activities in order to
ensure organismal preservation and maximal lifespan, despite an
increase in cellular senescence and apoptosis.
The level of injury in the cells of these patients is not only
exacerbated by the loss of antioxidative defense, but also by the
downregulation of oxidative phosphorylation and the shutdown of
protein synthesis and translation, as was observed in the gene
expression analysis of patients with lower levels of frataxin as
compared to patients with higher levels. EPIG analysis further
demonstrated a marked decrease in genes involved in protein
synthesis, and genes encoding ribosomal proteins, correlating with
frataxin levels, age of diagnosis, and ICARS scores. Many of the
significant genes involved in the category of protein synthesis
include the repression of several initiation factors. Paschen et al.
[64] discuss how such events suggest the relationship between the
shutdown of translation and induction of neuronal cell death. It is
our hypothesis that such global responses are triggered by chronic
stress.
We also found interesting the effect frataxin deficiency has on
ubiquitin cycle and protein degradation in both FRDA children
and FRDA adults. Modifications to the function of ubiquitinating
enzymes by oxidative stress have been reported [4]. Degradation
of damaged proteins by the ubiquitin-proteasome system (UPS) is
one of the most important processes in the cell, and a decreased
capacity for protein degradation is related to several neurodegen-
erative diseases and pathologies of the inflammatory immune
response [65,66].
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mitochondrial and nuclear DNA damage, as well as gene
expression patterns consistent with DNA damage, in peripheral
blood cells of patients with FRDA. Analyses of clinical features and
gene expression patterns correlate with age of onset and frataxin
mRNA levels, as well as altered protein synthesis with frataxin
levels, ICARS score, and age of diagnosis. Future studies with
Friedreich’s ataxia patients will help better define these gene sets
and DNA damage as candidate biomarkers of disease severity and
progression. Additionally, biomarkers are vital to the development
of therapeutic approaches, and our study points to possible drug
interventions, like modulating the ubiquitin-proteasome system or
upregulating molecular chaperone activity, which may be as useful
for FRDA as they are in other neurodegenerative diseases.
However, the development of effective therapeutic approaches
also depends on an enhanced understanding of signaling pathways
and other cellular responses to chronic genotoxic stress.
Materials and Methods
Ethics statement
Peripheral blood samples were collected from 48 children with
FRDA participating in a randomized, placebo-controlled clinical
trial for idebenone [registered with ClinicalTrials.gov, number
NCT00229632, and approved by the NIH Institutional Review
Board at the National Institute of Neurological Disorders and
Stroke (NINDS), protocol # 05-N-0245]. Samples from 14
anonymous FRDA adults were collected in the reference center
clinic dedicated to cerebellar ataxias and aspartic paraplegias at
the University Salpe ˆtrie `re Hospital in Paris; samples were
exempted by the NIH Institutional Review Board at the National
Institute of Environmental Health Sciences (NIEHS), exempt #
3984. All controls used for transcriptional profiling were young
healthy adults from an acetaminophen study [28], approved by the
Institutional Review Board at the University of North Carolina,
Chapel Hill, protocol # GCRC-2265. Controls used for the DNA
damage assay were obtained from an NIH blood bank. Blood
and/or apheresis samples were obtained from healthy volunteer
donors who gave signed consent to participate in an IRB-approved
protocol for use of their blood in laboratory research studies; these
samples were approved by the Institutional Review Board at the
National Cancer Institute (NCI), protocol # 99-CC-0168.
RNA isolation from blood
Peripheral blood samples were collected from 48 children with
FRDA participating in a randomized, placebo-controlled clinical
trial. All whole blood samples in this study were collected before
administration of idebenone. A detailed description of all subjects
and clinical endpoints was recently published [22]. Due to other
endpoints, this study only allotted one 8.5 ml sample of blood from
each patient for RNA isolation. RNA was isolated by one person,
utilizing the PAXgene blood RNA isolation kit (PreAnalytiX/
QIAGEN, Hilden, Germany) according to the manufacturer’s
protocol, including the optional on-column DNase digestion,
except that the centrifugation time after proteinase K digestion
was increased from 3 to 20 minutes in order to obtain a tighter
debris pellet. RNA quality was assessed with an Agilent
Bioanalyzer (Palo Alto, CA) to ensure that samples with intact
18S and 28S ribosomal RNA peaks were used for microarray
analysis. Of the 48 patients, twenty samples were lost during the
isolation procedures, leaving 28 high-quality RNA samples
remaining. The demographics for these subjects are detailed in
Table S1. RNA was also isolated, using the same methods already
described, from 14 anonymous FRDA adults (Table S2). All
controls used were young healthy adults (see demographics data in
Table S1 and Table S2) from an acetaminophen study [28]. Two
independent sets of control populations were used separately to
compare to the children and the adult validation cohort.
Gene profiling
Gene expression profiling was conducted using Agilent Human
1A(V2) Oligo arrays with ,20,000 genes represented (Agilent
Technologies, Palo Alto, CA). Each sample was hybridized against
a human universal RNA control (Stratagene, La Jolla, CA).
500 ng of total RNA was amplified and labeled using the Agilent
Low RNA Input Fluorescent Linear Amplification Kit, according
to manufacturer’s protocol. For each two color comparison,
750 ng of each Cy3- (universal control) and Cy5-labeled (sample)
cRNA were mixed and fragmented using the Agilent In Situ
Hybridization Kit protocol. Hybridizations were performed for
17 hours in a rotating hybridization oven according to the Agilent
60-mer oligo microarray processing protocol prior to washing and
scanning with an Agilent Scanner (Agilent Technologies, Wil-
mington, DE). The data were obtained with the Agilent Feature
Extraction software (v9.1), using defaults for all parameters. The
Feature Extraction Software performs error modeling before data
are loaded into a database system. Images and GEML files,
including error and p-values, were exported from the Agilent
Feature Extraction software and deposited into Rosetta Resolver
(version 5.0, build 5.0.0.2.48) (Rosetta Biosoftware, Kirkland,
WA). All gene expression data have been deposited in the public
Gene Expression Omnibus (GEO) database and are available
under the series ID GSE11204.
Statistical and data analyses
Supervised analysis to find genes associated with case versus
control or low frataxin expression versus high expression was
performed using Significance Analysis of Microarrays (SAM) after
pooling the raw data [29]. The two-class unpaired SAM algorithm
was used and the false discovery rate was set to less than or equal
to 1% for all analyses. Gene Set Analysis (GSA) [30] was also
performed for these comparisons to test the association of gene sets
instead of individual genes. The database of gene sets used for
GSA was obtained from the Molecular Signatures Database
(MSigDb) [30]. Gene sets demonstrating a p-value less than 0.01
were considered significant.
Biologically relevant themes in the lists of significant genes from
SAM were analyzed with gene ontology tools, GoMiner and
DAVID (Database for Annotation, Visualization and Integrated
Discovery) [67,68]. GO terms with p#0.05 for upregulated,
downregulated, and/or combined direction of change were
selected for analysis. Both tools group genes according to the
GO categories of biological process, cellular component, and
molecular function, based on ranking by a hypergeometric test p-
value. These data were also uploaded into Ingenuity Pathway
Analysis (IPA) software v 5.5.1 (Ingenuity Systems, Redwood City,
CA), a program that categorizes genes into biological functions but
also enables visualization of biologically relevant networks and
canonical pathways (‘‘canonical’’ implies ‘‘established’’). Go to
www.Ingenuity.com for specifics regarding the application.
Unsupervised clustering and heat-map generation were carried
out with Cluster and Treeview programs [69].
The levels of DNA damage were analyzed by Mann-Whitney U
test or Spearman’s Rank Correlation because the data is not
normally distributed or homoskedastic.
In order to test association between gene expression and age, we
used SAM. For the two DNA damage variables we used a
Student’s t-test to detect association with age. All these analyses
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comparison to the median age of the controls.
A univariate linear model was constructed to test the association
of each gene in the genotoxic gene set list (genes found in 25% of
gene lists from significant gene sets) to patient frataxin levels
(determined by Real-time PCR). Correlations of frataxin mRNA
levels to all available clinical data for each child were also
performed by univariate linear modeling.
In extracting gene expression patterns, EPIG [42] uses a filtering
process where all profiles initially are considered as pattern
candidates. Briefly, using all pair-wise correlations, any candidate
profile, whose local cluster size is less than a predefined size Mt or its
correlation with another profile is higher (.Rt) but has a lower local
cluster size M, is removed from pattern construction consideration.
Among the remaining profiles, EPIG then creates representative
profiles for the corresponding local clusters and removes those
profiles with a signal-to-noise ratio or magnitude less than given
thresholds. After this filtering processing, the remaining profiles
consist of the extracted patterns, which are used to be the
representatives to each of the local clusters. Subsequently, EPIG
categorizes each significant gene to a pattern, for which it has the
highest correlation with the gene profile. A gene not assigned to any
extractedpatternis consideredan ‘‘orphan’’ if its highestcorrelation
r-value is lower than the given threshold R.
TaqMan real-time PCR
The frataxin probe on the Agilent chip was observed to lack
sensitivity for both the individual lymphoblastoid cell lines from
affected people (data not shown) and the whole blood from FRDA
patients. We, therefore, decided to obtain relative gene expression
levels of frataxin by TaqMan Real-time PCR [70]. The sequence
information of the probe used for TaqMan is the proprietary
information of PE Applied Biosystems, but we know it is 75
nucleotides that span across the exon 1 and exon 2 boundary. On
the other hand, the probe on the microarray chip is mostly from
the 39 UTR of frataxin.
One microgram of total RNA from 27 patients and 10 controls
was used for reverse transcription with TaqMan Reverse
Transcription Reagents (PE Applied Biosystems). To determine
relative frataxin mRNA levels, Real-time PCR was carried out
using the ABI Prism 7900HT sequence detection system. Primer
and probe sets for frataxin and glucuronidase-beta were purchased
as pre-developed assays from PE Applied Biosystems. Relative
quantification was obtained using the threshold cycle method after
verification of primer performance, following the manufacturer’s
guidelines. The levels of frataxin obtained are relative to the
average DCT from 10 controls.
Mitochondrial and nuclear DNA quantitative PCR assay
Total DNA from whole blood was successfully isolated from 47
children enrolled in the study and 15 adult controls obtained from
an NIH blood bank in Bethesda, MD, (Table S6) using the
PAXgene blood DNA isolation kit (PreAnalytiX/QIAGEN,
Hilden, Germany) according to the instructions of the manufac-
turer. Briefly, one 8.5 ml sample of whole blood, per child, was
collected in PAXgene blood DNA tubes for DNA isolation; each
blood sample was transferred to a processing tube containing a
lysing solution. Lysed red and white blood cells were centrifuged,
and the resulting pellet of nuclei and mitochondria was washed
and resuspended. After digestion with protease, DNA was
precipitated by addition of isopropanol and dissolved in water.
All DNA samples were prepared by one person. DNA lesion
frequencies were calculated as described previously [33]. Briefly,
the amplification of patient samples (Apatient) was compared to the
amplification of non-damaged controls (Acontrol) resulting in a
relative amplification ratio. Assuming a random distribution of
lesions and using the Poisson equation [f(x)=.e ˜2l l
x/x!, where l is
the average lesion frequency for the nondamaged template (i.e.,
the zero class; x=0)], the average lesion per DNA strand was
determined by the following equation: . l= .2ln APatient/Acontrol.
Amplification of the large mitochondrial target was normalized
to mitochondrial copy number by examination of a short
mitochondrial target, which due to its short size, should be free
of damage.
Supporting Information
Figure S1 Stratification of Friedreich’s ataxia patients based on
the distribution of frataxin expression levels. A density plot of
frataxin (FXN) expression by Real-time PCR illustrates the
distribution of FXN expression over the cases. The x-axis indicates
the change in cycle threshold (ddCT) in the cases relative to a pool
of the controls. A threshold of 22.5 was selected to split the cases
into those with high expression of FXN (6 cases) versus those with
relatively low expression of FXN (21 cases).
Found at: doi:10.1371/journal.pgen.1000812.s001 (0.17 MB TIF)
Figure S2 GAA repeat length correlates with frataxin levels.
Individual FXN levels were determined for each patient by real-
time PCR. A univariate linear model was constructed to test the
association of frataxin mRNA levels with short GAA repeats. The
short GAA repeat length correlated with mRNA levels (r
2=0.338,
p=0.00131).
Found at: doi:10.1371/journal.pgen.1000812.s002 (0.17 MB TIF)
Figure S3 Gene Set Analysis finds gene sets in common between
the lymphoblastoid cell line and the FRDA children datasets.
Significantly associated gene sets from Gene Set Enrichment
Analysis subcatalog C2, a database of 1,684 microarray experi-
ment gene sets, pathways, and other groups of genes, were
identified for both the lymphoblastoid cell line and FRDA children
datasets. The analysis yielded many biologically informative sets
(n=171, p#0.05 and n=120, p#0.05 for the lymphoblastoids and
FRDA children, respectively) with 37 gene sets in common for the
two datasets. The Venn diagram displays 8 selected gene sets that
associate with both datasets. Descriptions in black loosely
summarize the gene set’s association to phenotype, cells, tissue,
or pathway as described by the authors of origin in the database.
Found at: doi:10.1371/journal.pgen.1000812.s003 (0.99 MB TIF)
Figure S4 Highly significant pathways responding to frataxin
reduction in FRDA patients are driven by downregulation.
Significant p-values were calculated by the right-tailed Fisher’s
Exact test using the entire dataset in the Ingenuity Pathway
Analysis program. (A) Significance of the top signaling and
metabolic pathways (p-value$0.05) in the complete list of
differentially expressed genes compared to that of downregulated
genes only (FDR,0.023%). Upregulated genes only did not reach
significance and were not included. (B) Frataxin deficiency
downregulates genes involved in the NRF2-mediated oxidative
stress pathway (adapted from the Ingenuity Pathway Analysis
Knowledge Base). Induced and repressed genes are depicted in
yellow and blue, respectively. Genes with no borders are
significant in FRDA children, genes with black borders are
significant in FRDA adults, and genes with red borders are
significant in both. Significant genes in FRDA children not shown:
FKBP5 (Q). Significant genes in FRDA adults not shown: ASK1
(Q), MEK5 (Q), JNK1/2 (Q), EIF2AK3 (Q), GSTO1 (Q), GSTA1
(q), GSTM3 (q), JUN (q), MAFG (Q), NQO1 (q).
Found at: doi:10.1371/journal.pgen.1000812.s004 (3.92 MB TIF)
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volved in gene expression analysis of peripheral blood.
Found at: doi:10.1371/journal.pgen.1000812.s005 (0.03 MB
DOC)
Table S2 Demographics for Friedreich’s ataxia adult subjects
involved in gene expression analysis of peripheral blood.
Found at: doi:10.1371/journal.pgen.1000812.s006 (0.03 MB
DOC)
Table S3 The complete list of GO terms associated to the 228
significant genes in common between the FRDA children and
FRDA adults.
Found at: doi:10.1371/journal.pgen.1000812.s007 (0.06 MB
DOC)
Table S4 Ingenuity Pathway Analysis. Ingenuity Knowledge
Base biological function categories and pathways associated to the
overlap of 228 significant genes from the FRDA children and
FRDA adults, respectively (p$0.05).
Found at: doi:10.1371/journal.pgen.1000812.s008 (0.11 MB
RTF)
Table S5 Gene Set Analysis of common genes. Enriched gene
sets associated to significant genes (SAM) that overlap between
FRDA children and FRDA adults.
Found at: doi:10.1371/journal.pgen.1000812.s009 (0.04 MB
DOC)
Table S6 Demographics for Friedreich’s ataxia children in-
volved in DNA damage analysis of peripheral blood.
Found at: doi:10.1371/journal.pgen.1000812.s010 (0.03 MB
DOC)
Table S7 Gene names and corresponding IDs.
Found at: doi:10.1371/journal.pgen.1000812.s011 (0.19 MB
RTF)
Table S8 Demographic data for FRDA and control lympho-
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